Cancer Research Technology
Log in Register
Menu

ZH3D7:BCAR1 [D4E5] Fusion cell line
NEW

Info

Catalogue Number 154639
Antigen/Gene or Protein Targets BCAR1
Parental Line ZH3D7
Synonyms Breast Cancer Anti-Estrogen Resistance 1; CASS1; P130Cas; CRKAS
Host Human
Tissue Breast
Disease Keywords Mammary ductal carcinoma, estrogen independent
Model Cancer Model
Relevance Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype. Somatic cell fusion was used to generate this cell line in order to elucidate the molecular mechanisms underlaying endocrine therapy failure. Using this method revealed that tamoxifen resistance co-segregated with only 1 or 2 of the integration loci present in the tamoxifen-resistant donor cell line, designated the first breast cancer anti-estrogen resistance locus (BCAR1)

This cell line is part of a panel of 3 somatic hybrids (Cat No 154639-154641) plus the parental (Cat 154620).

This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression and therapy resistance.
Production Details Hygromycin-B-resistant variants of ZR-75-1 cells, ZH3D7, were used as recipients in the somatic-cell-fusion experiments. Donor cells were the anti-estrogen-resistant cell line XI-13. Approximately 6 million donor cells, which were gamma-irradiated with approx 40 Gy and 3 million recipient cells were plated in 25cm flasks in RBCS medium with estradiol. After strong adherence to the flasks in 36 to 48 hr, cells were washed 3 times in RPMI-1640 without serum and incubated with 1 ml polyethylene glycol (PEG) 1500 at 30–34°C for 1 min on a stretching table. The PEG solution was diluted with1, 2 and 4 ml RPMI-1640 after 1, 2 and 4 min respectively. Finally,cells were washed 3 times with RPMI-1640 and incubated for 2days at 37°C in RBCS medium with estradiol. Selection with 1mg/ml G418 in RBCS medium plus estradiol was performed for one week followed by one week of selection with 50 µg/ml hygromycin B. After an additional week of selection with G418, colonies were picked and expanded to cell lines in RBCS medium containing estradiol and G418
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions R/BCS medium containing estradiol and Geneticin (G418)
Notes This cell line is resistant to hygromycin and Genticin and are maintained in RBCS medium with estradiol and Geneticin. Since they carry a BCAR gene, that can also proliferate slowly in medium without estradiol and supplemented with anti-estrogen.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.


Add a reference

References: 1 entry

Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor